论文部分内容阅读
目的通过对患者血浆游离DNA的定量检测,探索一种可用于卵巢上皮性癌早期诊断和疗效监控的新方法。方法2001年4月至2003年2月上海市肿瘤研究所等单位以微量基因组抽提试剂盒抽提血浆DNA,以SYBR Green I斑点荧光染色法分别检测93例卵巢上皮性癌、25例卵巢良性肿瘤及100例健康对照标本血浆游离DNA含量。结果卵巢上皮性癌血浆游离DNA质量浓度为(82.1±60.6)μg/L,卵巢良性肿瘤为(21.1±17.6)μg/L,健康对照组为(14.9±8.2)μg/L,卵巢上皮性癌患者血浆游离DNA质量浓度明显高于正常对照及卵巢良性肿瘤,差异有显著性(P<0.001)。血浆游离DNA质量浓度与病理类型及组织学分级无关,但与临床分期相关,IV期癌较其他三期升高明显(P=0.016)。在I期卵巢上皮性癌患者中,血浆游离DNA质量浓度已达(68.8±46.1)μg/L,显著高于卵巢良性肿瘤和健康对照人员(P<0.001)。结论卵巢上皮性癌游离DNA定量检测有可能成为一种新的卵巢上皮性癌血浆标志物检测方法。
Objective To explore a new method for the early diagnosis and treatment of ovarian epithelial carcinoma by quantitative detection of plasma free DNA in patients. Methods From April 2001 to February 2003, Shanghai Institute of Oncology and other institutes extracted plasma DNA with micro genomic extraction kit and detected 93 cases of epithelial ovarian cancer, 25 cases of benign ovarian benign disease by SYBR Green I speckle staining, Tumor and 100 healthy controls plasma free DNA content. Results The plasma concentrations of free DNA in epithelial ovarian cancer were (82.1 ± 60.6) μg / L, (21.1 ± 17.6) μg / L benign ovarian tumors and (14.9 ± 8.2) μg / L in healthy controls, respectively. Plasma concentrations of free DNA in patients were significantly higher than those in normal controls and benign ovarian tumors, the difference was significant (P <0.001). The plasma concentration of free DNA was not related to pathological type and histological grade, but correlated with clinical stage. Stage IV cancer was significantly higher than the other three stages (P = 0.016). In stage I patients with epithelial ovarian cancer, plasma free DNA mass concentration (68.8 ± 46.1) μg / L was significantly higher than benign ovarian tumors and healthy controls (P <0.001). Conclusion Quantitative detection of free DNA in epithelial ovarian cancer may become a new detection method of plasma markers of epithelial ovarian cancer.